4,510,716 Shares in CVS Health Corporation $CVS Purchased by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in CVS Health Corporation (NYSE:CVS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,510,716 shares of the pharmacy operator’s stock, valued at approximately $466,634,000.

Several other hedge funds also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of CVS Health in the 4th quarter valued at approximately $1,666,265,000. Wellington Management Group LLP boosted its position in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after purchasing an additional 12,233,675 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of CVS Health during the 2nd quarter worth approximately $932,454,000. Pacer Advisors Inc. increased its holdings in CVS Health by 1,020.7% in the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock valued at $347,984,000 after purchasing an additional 4,412,882 shares during the last quarter. Finally, Amundi raised its position in CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Performance

NYSE:CVS opened at $93.99 on Tuesday. CVS Health Corporation has a 52 week low of $69.40 and a 52 week high of $110.68. The company has a fifty day simple moving average of $102.46 and a two-hundred day simple moving average of $88.41. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The company has a market cap of $120.21 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same period last year, the firm earned $1.81 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 70.37%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CVS. Truist Financial lifted their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Barclays increased their target price on CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley raised their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Cantor Fitzgerald boosted their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Finally, Robert W. Baird set a $107.00 price target on shares of CVS Health in a research report on Thursday, August 6th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $106.75.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.